vTv Therapeutics Appoints New CFO Amidst Phase 3 Trial

An announcement from vTv Therapeutics ( (VTVT) ) is now available.

On May 19, 2025, vTv Therapeutics announced the appointment of Michael Tung as Executive Vice President and Chief Financial Officer. Dr. Tung brings over 20 years of experience in financial management and strategic leadership in the life sciences industry. His appointment coincides with the company’s reinitiation of its Phase 3 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes, marking a critical inflection point for the company as it advances its development goals.

The most recent analyst rating on (VTVT) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on vTv Therapeutics stock, see the VTVT Stock Forecast page.

Spark’s Take on VTVT Stock

According to Spark, TipRanks’ AI Analyst, VTVT is a Underperform.

vTv Therapeutics’ overall stock score reflects significant financial difficulties and a speculative valuation, balanced by positive developments in its clinical trials. While the corporate events suggest future potential, the current financial instability and lack of profitability weigh heavily on the stock’s attractiveness.

To see Spark’s full report on VTVT stock, click here.

More about vTv Therapeutics

vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. The company’s clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes.

Average Trading Volume: 22,660

Technical Sentiment Signal: Buy

Current Market Cap: $67.18M

Learn more about VTVT stock on TipRanks’ Stock Analysis page.